Uncovering Proteomic Biomarkers Linking Type 2 Diabetes to Cardiovascular Risk
About this webinar
Glucose metabolism disturbances, particularly type 2 diabetes (T2D), are significant risk factors for cardiovascular disease. However, the biomarkers for atherosclerosis development in patients with T2D or prediabetes remain largely unexplored.
In this webinar, cardiovascular expert Prof. Karol Kaminski, MD, PhD, will present a study that contributes to closing this gap in research. This study identified proteomic biomarkers in individuals with untreated glucose metabolism disturbances who are not diagnosed with diabetes, chronic inflammatory, neoplastic, or cardiovascular disease.
Using an innovative high-throughput proteomic analysis method, which measures approximately 1,000 abundance proteins in plasma across a wide range of biological pathways, numerous proteins have been identified that distinguish healthy controls from those with prediabetes and T2D.
Join this webinar to gain insights into how specific proteins can indicate more severe metabolic disorders and provide a better understanding of the pathogenesis of cardiovascular disease in diabetic patients.
Who should attend
- Scientists interested in identifying diseases specific biomarkers leveraging simplified and accessible proteomics solutions
- Biomarker Scientist/Assay Scientist/Translational Scientist/Protein Scientist
- R&D Lead/Clinical Biomarker Lead
- Post-Doctoral Researcher/Research Fellow
- Researcher/Senior Research Associate
- Associate/Full Professor
- Professionals in pharma/biotech companies
- Contract research organizations
What you will learn
- The proteins that differentiate healthy individuals, those with prediabetes and those with T2D
- How protein markers can link diabetes to heart disease
- The methods for plasma protein analysis and their applications in identifying cardiometabolic biomarkers
Featured Speakers
Prof. Karol Kaminski, MD, PhD
Professor Karol Kamiński, MD, PhD, is a distinguished cardiologist and full professor at the Medical University of Białystok in Poland. He serves as the Head of the Department of Cardiology and Internal Medicine, which includes the Cardiac Intensive Care Unit.
After studies that included attachments at Harvard Medical School, Heidelberg University, St. Thomas’ School of Medicine in London and St. George’s School of Medicine in London, he graduated from the Medical University of Białystok in 1999.
He had research fellowships in experimental cardiology in Harvard Medical School and Hannover Medical School. He has been the Fellow of the European Society of Cardiology, recipient of multiple awards from the Polish Society of Cardiology, European Society of Cardiology, Ministry of Health and Rector of the Medical University of Bialystok.
Professor Kamiński is the recipient of Ministry of Science scholarship postgraduate course in science, commercialization and innovation at Stanford University. He is the Vice-Rector of the Medical University of Bialystok and is the co-author of papers published in renowned international journals, including Cell, Circulation, FASEB, International Journal of Cardiology and European Journal of Heart Failure. He is the PI of a general population-based cohort study Bialystok PLUS.
Fanny Taborsak-Lines, MSc
Fanny Taborsak-Lines has a MSc in bioengineering from Chalmers University of Technology, Gothenburg. Before joining Olink, she worked as team leader for the Laboratory Development group at the National Genomics Infrastructure, SciLifeLab, Stockholm, driving implementation, automation and scaling of new sequencing applications.
Partner for this event
Olink
Olink’s mission is to accelerate proteomics together with the scientific community, to understand real-time biology and gain actionable insights into human health and disease.
Our innovative solutions deliver highly sensitive and accurate protein quantification, giving scientists the power to investigate complex biological processes with precision.